Brief: Moleculin Biotech Receives NASDAQ Letter On Regaining Compliance With Bid Price Rule 5550(A)(2)
08/04/2024 22:24
April 8 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN BIOTECH- CO RECEIVED LETTER FROM NASDAQ
NOTIFYING
COMPANY THAT IT HAD REGAINED COMPLIANCE WITH BID PRICE RULE
5550(A)(2)
Source text for Eikon: ID:n0001437749-24-011423
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM